These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 20345970)

  • 1. Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.
    Fuxe K; Marcellino D; Borroto-Escuela DO; Guescini M; Fernández-Dueñas V; Tanganelli S; Rivera A; Ciruela F; Agnati LF
    CNS Neurosci Ther; 2010 Jun; 16(3):e18-42. PubMed ID: 20345970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology.
    Fuxe K; Marcellino D; Rivera A; Diaz-Cabiale Z; Filip M; Gago B; Roberts DC; Langel U; Genedani S; Ferraro L; de la Calle A; Narvaez J; Tanganelli S; Woods A; Agnati LF
    Brain Res Rev; 2008 Aug; 58(2):415-52. PubMed ID: 18222544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the role of heteroreceptor complexes in the central nervous system.
    Fuxe K; Borroto-Escuela D; Fisone G; Agnati LF; Tanganelli S
    Curr Protein Pept Sci; 2014; 15(7):647. PubMed ID: 25256022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function.
    Fuxe K; Ferré S; Genedani S; Franco R; Agnati LF
    Physiol Behav; 2007 Sep; 92(1-2):210-7. PubMed ID: 17572452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophrenia.
    Fuxe K; Marcellino D; Woods AS; Giuseppina L; Antonelli T; Ferraro L; Tanganelli S; Agnati LF
    J Neural Transm (Vienna); 2009 Aug; 116(8):923-39. PubMed ID: 19156349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus.
    Bonaventura J; Rico AJ; Moreno E; Sierra S; Sánchez M; Luquin N; Farré D; Müller CE; Martínez-Pinilla E; Cortés A; Mallol J; Armentero MT; Pinna A; Canela EI; Lluís C; McCormick PJ; Lanciego JL; Casadó V; Franco R
    Neuropharmacology; 2014 Apr; 79():90-100. PubMed ID: 24230991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for adenosine/dopamine receptor interactions: indications for heteromerization.
    Franco R; Ferré S; Agnati L; Torvinen M; Ginés S; Hillion J; Casadó V; Lledó P; Zoli M; Lluis C; Fuxe K
    Neuropsychopharmacology; 2000 Oct; 23(4 Suppl):S50-9. PubMed ID: 11008067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia.
    Ferré S
    Psychopharmacology (Berl); 1997 Sep; 133(2):107-20. PubMed ID: 9342776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
    Morin N; Di Paolo T
    Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine A(2A) Receptors and A(2A) Receptor Heteromers as Key Players in Striatal Function.
    Ferré S; Quiroz C; Orru M; Guitart X; Navarro G; Cortés A; Casadó V; Canela EI; Lluis C; Franco R
    Front Neuroanat; 2011; 5():36. PubMed ID: 21731559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders.
    Ferré S; Ciruela F; Canals M; Marcellino D; Burgueno J; Casadó V; Hillion J; Torvinen M; Fanelli F; Benedetti Pd Pd; Goldberg SR; Bouvier M; Fuxe K; Agnati LF; Lluis C; Franco R; Woods A
    Parkinsonism Relat Disord; 2004 Jul; 10(5):265-71. PubMed ID: 15196504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers.
    Soriano A; Ventura R; Molero A; Hoen R; Casadó V; Cortés A; Fanelli F; Albericio F; Lluís C; Franco R; Royo M
    J Med Chem; 2009 Sep; 52(18):5590-602. PubMed ID: 19711895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells.
    Cabello N; Gandía J; Bertarelli DC; Watanabe M; Lluís C; Franco R; Ferré S; Luján R; Ciruela F
    J Neurochem; 2009 Jun; 109(5):1497-507. PubMed ID: 19344374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.
    Tanganelli S; Sandager Nielsen K; Ferraro L; Antonelli T; Kehr J; Franco R; Ferré S; Agnati LF; Fuxe K; Scheel-Krüger J
    Parkinsonism Relat Disord; 2004 Jul; 10(5):273-80. PubMed ID: 15196505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum.
    Orrú M; Quiroz C; Guitart X; Ferré S
    Neuropharmacology; 2011; 61(5-6):967-74. PubMed ID: 21752341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
    Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
    Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease.
    Fuxe K; Marcellino D; Genedani S; Agnati L
    Mov Disord; 2007 Oct; 22(14):1990-2017. PubMed ID: 17618524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boolean analysis shows a high proportion of dopamine D
    Rivas-Santisteban R; Rico AJ; Muñoz A; Rodríguez-Pérez AI; Reyes-Resina I; Navarro G; Labandeira-García JL; Lanciego JL; Franco R
    Neurobiol Dis; 2023 Nov; 188():106341. PubMed ID: 37918757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors.
    Díaz-Cabiale Z; Vivó M; Del Arco A; O'Connor WT; Harte MK; Müller CE; Martínez E; Popoli P; Fuxe K; Ferré S
    Neurosci Lett; 2002 May; 324(2):154-8. PubMed ID: 11988350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice.
    Chen JF; Moratalla R; Impagnatiello F; Grandy DK; Cuellar B; Rubinstein M; Beilstein MA; Hackett E; Fink JS; Low MJ; Ongini E; Schwarzschild MA
    Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1970-5. PubMed ID: 11172060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.